Literature DB >> 2209254

Pharmacokinetic considerations in understanding nicotine dependence.

N L Benowitz1.   

Abstract

The pharmacokinetic and pharmacodynamic characteristics of a drug are important determinants of whether users become dependent on it and of the temporal patterns of drug use. Characteristics of cigarette smoking, which produces a high degree of dependence, and the use of nicotine gum, which has a relatively low risk of dependence, are compared. Nicotine from tobacco smoke is rapidly absorbed and transferred into the brain. This results in high brain concentrations and intensive psychological effects, with relatively little development of tolerance. The smoker may titrate the level of drug and associated psychological effects of nicotine. Thus, smoking provides a nearly optimal situation for behavioural reinforcement. Chewing nicotine gum results in slow absorption of nicotine, leading to lower levels of nicotine in the brain and substantial time for development of tolerance. Thus, the intensity of effect is less and the onset of effect is delayed from the onset of dosing, providing less opportunity for behavioural reinforcement. Pharmacokinetic and pharmacodynamic modelling techniques have been applied to these processes and used to assess the implications for understanding the daily smoking cycle.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2209254     DOI: 10.1002/9780470513965.ch11

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  12 in total

1.  Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample.

Authors:  S Shiffman; J R Hughes; J L Pillitteri; S L Burton
Journal:  Tob Control       Date:  2003-09       Impact factor: 7.552

2.  Sex differences in nicotine levels following repeated intravenous injection in rats are attenuated by gonadectomy.

Authors:  Steven B Harrod; Rosemarie M Booze; Charles F Mactutus
Journal:  Pharmacol Biochem Behav       Date:  2006-12-20       Impact factor: 3.533

Review 3.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

4.  Dependence on tobacco and nicotine products: a case for product-specific assessment.

Authors:  Karl Fagerström; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2012-03-29       Impact factor: 4.244

Review 5.  Nicotine: abused substance and therapeutic agent.

Authors:  J Le Houezec
Journal:  J Psychiatry Neurosci       Date:  1998-03       Impact factor: 6.186

Review 6.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

7.  Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats.

Authors:  Samuel A Roiko; Andrew C Harris; Mark G LeSage; Daniel E Keyler; Paul R Pentel
Journal:  Pharmacol Biochem Behav       Date:  2009-04-23       Impact factor: 3.533

8.  Physiological effects of infant exposure to environmental tobacco smoke: a passive observation study.

Authors:  M B Flanders-Stepans; S G Fuller
Journal:  J Perinat Educ       Date:  1999

Review 9.  Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.

Authors:  Enrique L M Ochoa; Jose Lasalde-Dominicci
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

10.  Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking.

Authors:  Ami Cohen; Olivier George
Journal:  Front Psychiatry       Date:  2013-06-04       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.